Tzield Approval Expands to Younger Patients
First disease-modifying option available for children as young as 1 year with stage 2 type 1 diabetes
-
By
-
Kathryn Wighton
-
April 22, 2026
-
Clinical Scorecard: Tzield Approval Expands to Younger Patients
At a Glance
| Category | Detail |
|---|
| Condition | Type 1 Diabetes (T1D) |
| Key Mechanisms | CD3-directed monoclonal antibody targeting to delay disease progression |
| Target Population | Pediatric patients aged 1 year and older with stage 2 T1D |
| Care Setting | Outpatient, pediatric care |
Key Highlights
- FDA approved teplizumab-mzwv (Tzield) for younger pediatric patients
- Indicated for delaying onset of stage 3 T1D in patients aged 1 year and older
- Approval based on PETITE-T1D Phase 4 study data
- Previously approved for patients aged 8 years and older
- Teplizumab received breakthrough therapy and orphan drug designations
Guideline-Based Recommendations
Diagnosis
- Diagnosis of stage 2 T1D requires presence of at least two diabetes-related autoantibodies and dysglycemia.
Management
- Administer teplizumab intravenously once daily for 14 consecutive days.
Monitoring & Follow-up
- Follow-up for up to 26 months post-treatment to assess safety and efficacy.
Risks
- Potential for adverse effects related to immunomodulation.
Patient & Prescribing Data
Children younger than 8 years with stage 2 T1D
Effective in delaying the onset of stage 3 T1D.
Clinical Best Practices
- Ensure proper diagnosis of stage 2 T1D before treatment initiation.
- Monitor patients closely for signs of progression to stage 3 T1D.
- Educate families on the importance of follow-up and management of T1D.
Related Resources & Content
